newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025